Lovaza®: Potent, pure, and proven?
Metadata[+] Show full item record
Lovaza (omega-3-acid ethyl esters), formerly Omacor®, is a combination prescription formulation of 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA) approved in the United States for the treatment of patients with hypertriglyceridemia (≥500 mg/dL). One study has shown efficacy with Lovaza for secondary prevention of coronary heart disease (CHD) events. Over-the-counter (OTC) omega-3 products have been studied more widely and have demonstrated efficacy in both primary and secondary prevention.
Evidence Based Practice 11(3): 10-11.